High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to develo** more efficient cancer detection methods and …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Bladder cancer is among the ten most common cancers globally, causes considerable
morbidity and mortality and is, therefore, a substantial burden for health-care systems. The …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

Histomorphology has been a mainstay of cancer diagnosis in anatomic pathology for many
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …

Background Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are
common in urothelial carcinoma and may be associated with lower sensitivity to immune …